Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

SDZ MSL-109

Small molecule

NNational Center for Research Resources (NCRR)

SDZ MSL-109 is one of 2 small molecule programs targeting Central Nervous System Disease. It is currently in development.

1

Indications

1

Total Trials

0

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

Central Nervous System DiseaseActive, not recruiting

Central Nervous System DiseasePhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

1 competitor in Central Nervous System Disease

#DrugCompanyPhaseTrials

Enzastaurin

SDZ MSL-109

NNational Center for Research Resources (NCRR)

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Central Nervous System Disease1 trial

Phase I/II Study of Human Anti-Cytomegalovirus (CMV) Monoclonal Antibody MSL-109 in Newborns With Symptomatic Congenital CMV Infection Without Central Nervous System Disease

Completed·NNational Center for Research Resources (NCRR)·Phase 1/2·NCT00004642

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SDZ MSL-109. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SDZ MSL-109 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SDZ MSL-109. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Center for Research Resources (NCRR) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: NNational Center for Research Resources (NCRR)

Related News